Participation of adenosine receptors in neuroprotection

Drug News and Perspectives

Volumn 16, Issue 2, 2003, Pages 80-86

  Ribeiro, J A ^a   Sebastiao A M ^b   De Mendonca A ^b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ALZHEIMER DISEASE; AROUSAL; CELL FUNCTION; COGNITION; DEGENERATIVE DISEASE; EPILEPSY; GLIA CELL; MEMORY; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SLEEP;

ADENOSINE; DRUG DESIGN; HUMANS; MENTAL PROCESSES; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY; RECEPTORS, PURINERGIC P1; SYNAPTIC TRANSMISSION;

EID: 0038609688     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.2.740246     Document Type: Review

References (64)

1. Engler, R.L. Adenosine, the signal of life? Circulation 1991, 84: 951-4.
2. Di Iorio, P., Kleywegt, S., Ciccarelli, R. et al. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 2002, 38: 179-90.
3. Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.-N. and Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53: 527-52.
4. Linden, J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001, 41: 775-87.
5. Hervé, D., Le Moine, C., Corvol, J.C. et al. G(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 2001, 21: 4390-9.
6. Sebastião, A.M., de Mendonça A. and Ribeiro, J.A. Neuroprotection during hypoxic insults: Role of adenosine. Drug Devel Res 2001, 52: 291-5.
7. 3H]GABA release from rat hippocampal nerve terminals. Neuropharmacol 2000, 39: 1156-67.
8. 2a receptor is not mediated by increases in cyclic AMP. J Neurochem 1995, 64: 2801-9.
9. Ferré, S., Fredholm, B.B., Morelli, M., Popoli, P. and Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997, 20: 482-7.
10. Sebastião, A.M. and Ribeiro. J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 2000, 21: 341-6.
11. Lee, F.S and Chao, M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 2001, 98: 3555-60.
12. Corset, V., Nguyen-Ba-Charvet, K.T., Forcet, C., Moyse, E., Chedotal, A. and Mehlen, P. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 2000, 407: 747-50.
13. 2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. J Neurophysiol 1996, 76: 3910-9.
14. de Mendonça, A., Sebastião, A.M. and Ribeiro, J.A. Adenosine: Does it have a neuroprotective role after all? Brain Res Rev 2000, 33: 258-74.
15. Sun, M.K., Xu, H. and Alkon, D.L. Pharmacological protection of synaptic function, spatial learning, and memory from transient hypoxia in rats. J Pharmacol Exp Ther 2002, 300: 408-16.
16. Dunwiddie, T.V. and Masino, S.A. The role and regulation of adenosine in the central nervous system. Ann Rev Neurosci 2001, 24: 31-55.
17. 1 receptor activation. NeuroReport 1995, 6: 1097-100.
18. Sebastiao, A.M., de Mendonça, A., Moreira, T. and Ribeiro J.A. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 2001, 21: 8564-71.
19. Sattler, R., Xiong, Z., Lu, W.Y., MacDonald, J.F., Tymianski, M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J Neurosci 2000, 20: 22-33
20. Hardingham, G.E., Fukunaga, Y. and Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002, 5: 405-14.
21. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999, 19: 9192-200.
22. Cassada, D.C., Tribble, C.G., Kaza, A.K. et al. Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery 2001, 130: 230-5.
23. Ohta, A. and Sitkovsky, M. Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 2001, 414: 916-20.
24. 2A receptor in the rat carotid body. Am J Physiol Lung Cell Mol Physiol 2000, 279: L273-82.
25. Ribeiro, J.A. Adenosine and the central nervous system control of autonomic function. In: Adenosine in the Nervous System. TW. Stone (Ed.) Academic Press, London 1991, 229-46.
26. 3 receptors in cerebral ischemia. Neuronal death, recovery, or both? Ann NY Acad Sci 1999, 890: 93-106.
27. Jacobson, K.A., von Lubitz, D.K., Daly, J.W. and Fredholm, B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996, 17: 108-13.
28. de Mendonça, A. and Ribeiro, J.A. Adenosine and synaptic plasticity. Drug Devel Res 2001, 52: 283-90.
29. Stone, T.W., Collis, M.G., Williams, M., Miller, L.P., Karasawa, A. and Hillaire-Buys, D. Adenosine: Some therapeutic applications and prospects. In: Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s. A.C. Cuello and B. Collier (Eds.). Birkhäuser Verlag, Basel 1995, 303-9.
30. Fredholm, B.B., Bätig, K., Holmén, J., Nehlig, A. and Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999, 51: 83-133.
31. 2 receptor blockade on spatial memory performance of rats: Selective enhancement of reference memory retention during the light period. Behav Brain Res 2001, 118: 43-52.
32. Maia, L. and de Mendonça, A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 2002, 9: 1-6.
33. Doody, R.S., Stevens, J.C., Beck, C. et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56: 1154-66.
34. Fuxe, K., Stromberg, I., Popoli, P. et al. Adenosine receptors and Parkin-son's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 2001, 86: 345-53.
35. 2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 2001, 22: 71-2.
36. 2A antagonists in PD. Neurology 2002, 58: 1154-60.
37. 2 receptors for dopamine in human striatum. Neuroreport 2001, 12: 1831-4.
38. 2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001, 41: 160-71.
39. 2A receptors in the caudateputamen of rats. J Neurosci 2001, 14: 1287-93.
40. Dall'Igna, O.P., Dietrich, M.O., Hoffmann, A. et al. Catalepsy and hypolocomotion induced by a nitric oxide donor: Attenuation by theophylline. Eur J Pharmacol 2001, 432: 29-33.
41. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001, 21: RC143 (1-6).
42. Mally, J. and Stone, T.W. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 1994, 46: 515-7.
43. Ross, G.W., Abbott, R.D., Petrovitch, H. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283: 2674-9.
44. Ascherio, A., Zhang, S.M., Hernan, M.A. et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50: 56-63.
45. Ferré, S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacol 1997, 133: 107-20.
46. 2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother 1999, 33: 480-8.
47. Akhondzadeh, S., Shasavand, E., Jamilian, H., Shabestari, O. and Kamalipour, A. Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. J Clin Pharm Ther 2000, 25: 131-7.
48. Dragunow, M. Adenosine: The brain's natural anticonvulsivant? Trends Pharmacol Sci 1986, 7: 128-30.
49. 6-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. Neuropharmacology 2001, 40: 657-67.
50. 1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 1999, 45: 633-9.
51. 1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001, 49: 650-8.
52. 1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res 1995, 692: 79-85.
53. Porkka-Heiskanen, T., Strecker, R.E., Thakkar, M., Bjorkum, A.A., Greene, R.W. and McCarley, R.W. Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997, 276: 1265-8.
54. Antle, M.C., Steen, N.M., Mistlberger, R.E. Adenosine and caffeine modulate circadian rhythms in the Syrian hamster: Neuroreport 2001, 12: 2901-5.
55. 1 receptors regulate the response of the hamster circadian clock to light. Eur J Pharmacol 2001, 414: 45-53.
56. 2A receptors modulate sleep state and breathing in fetal sheep. J Appl Physiol 2001, 91: 343-50.
57. van Dongen, H.P., Price, N.J., Mullington, J.M., Szuba, M.P., Kapoor, S.C. and Dinges, D.F. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep 2001, 24: 813-9.
58. Adén, U., Herlenius, E., Tang, L.Q. and Fredholm, B.B. Maternal caffeine intake has minor effects on adenosine receptor ontogeny in the rat brain. Pediatr Res 2000, 48: 177-83.
59. Rivkees, S.A., Zhao, Z., Porter, G. and Turner, C. Influences of adenosine on the fetus and newborn. Mol Genet Metab 2001, 74: 160-71.
60. Drury, A.N. and Szent-Györgyi, A. The physiological activity of adenine compounds with espetial reference to their action upon the mammalian heart. J Physiol 1929, 68: 213-37.
61. Barraco, R.A., Aggarwal, A.K., Phillis, J.W., Moron, M.A. and Wu, P.H. Dissociation of the locomotor and hypotensive effects of adenosine analogues in the rat. Neurosci Lett 1984, 48: 139-44.
62. Impagnatiello, F., Bastia, E., Ongini, E. and Monopoli, A. Adenosine receptors in neurological disorders. Emerging Therap Targets 2000, 4: 635-64.
63. Kowaluk, E.A. and Jarvis, M.F. Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 2000, 9: 551-64.
64. 6-substituted adenosine derivatives as partial agonists of rat brain adenosine receptors. Eur J Pharmacol 1997, 334: 299-307.